Gyre Therapeutics, Inc. Temporary Equity, Liquidation Preference
Gyre Therapeutics, Inc. (GYRE) had Temporary Equity, Liquidation Preference of $0 as of 2015-12-31, per its 10-K filed 2016-03-09.
Discontinued › Balance Sheet › Equity › Temporary Equity › Temporary Equity, Other Disclosure
us-gaap:TemporaryEquityLiquidationPreference · last filed 2016-03-09
- 2015-12-31: Temporary Equity, Liquidation Preference $0.00.
- 2015-09-30: Temporary Equity, Liquidation Preference $0.00.
- 2014-12-31: Temporary Equity, Liquidation Preference $118.68M.
| Period end | Temporary Equity, Liquidation Preference |
|---|---|
| 2015-12-31 | $0.00 10-K · filed 2016-03-09 |
| 2015-09-30 | $0.00 10-Q · filed 2015-11-05 |
| 2014-12-31 | $118.68M 10-K · filed 2016-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |